Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Autobahn Therapeutics

    Menu

    Autobahn Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Autobahn Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress

              Details:

              ABX-002 is a novel, orally administered, potent, and selective thyroid hormone beta agonist, which is investigated for the treatment of major depressive disorder.

              Lead Product(s): ABX-002

              Therapeutic Area: Psychiatry/Psychology Product Name: ABX-002

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autobahn Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial

              Details:

              ABX-002 is an orally administered, potent, selective thyroid hormone beta (TRβ) agonist that is brain enhanced, demonstrates target engagement in brain regions associated with depression.

              Lead Product(s): ABX-002

              Therapeutic Area: Psychiatry/Psychology Product Name: ABX-002

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autobahn Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

              Details:

              Autobahn has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversions.

              Lead Product(s): ASP3652,ABX-003

              Therapeutic Area: Immunology Product Name: ASP3652

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Astellas Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition May 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autobahn Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

              Details:

              Administration of ABX-002 resulted in potent and on-target responses in preclinical models of AMN and support company's continued advancement of ABX-002 toward clinical evaluation for the treatment of people with this rare and very difficult disease.

              Lead Product(s): ABX-002

              Therapeutic Area: Genetic Disease Product Name: ABX-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autobahn Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA

              Details:

              Autobahn has gained alignment with FDA on the initial Phase 1a/b clinical trial protocol for ABX-002 as a monotherapy treatment for a rare neurological disorder, adrenomyeloneuropathy (AMN).

              Lead Product(s): ABX-002

              Therapeutic Area: Genetic Disease Product Name: ABX-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Autobahn Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders

              Details:

              Proceeds will be used to advance Autobahn’s lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN).

              Lead Product(s): ABX-002

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: ARCH Venture Partners

              Deal Size: $76.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing June 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY